NutriStack
What is happening. Valganciclovir (the oral prodrug of ganciclovir) commonly causes dose-limiting myelosuppression, including anemia. People taking it may be tempted to self-treat fatigue or a low hemoglobin with oral iron, but iron deficiency is frequently not the underlying cause of ganciclovir-associated anemia, which is typically due to direct bone marrow suppression. Empiric iron supplementation will not correct marrow-suppression anemia and may mask the need for dose reduction, growth-factor support, or transfusion.
Mechanism. Ganciclovir-induced anemia results from direct suppression of bone marrow precursors, not from depleted iron stores. Iron supplementation only corrects anemia driven by iron deficiency, so it does not address the drug-related mechanism and can delay appropriate evaluation.
Recommendation. Do not start oral iron for fatigue or anemia during valganciclovir therapy without first confirming true iron deficiency (ferritin, transferrin saturation) and discussing the cause of the anemia with the prescriber. Anemia during therapy should prompt a complete blood count and clinical review rather than self-treatment.